A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment

Oh Young Lee, Dae Hwan Kang, Dong Ho Lee, Il Kwun Chung, Jae Young Jang, Jin Il Kim, Jin Woong Cho, Jong Sun Rew, Kang Moon Lee, Kyoung Oh Kim, Myung Gyu Choi, Sang Woo Lee, Soo Teik Lee, Tae Oh Kim, Yong Woon Shin, Sang Yong Seol

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Misoprostol is reported to prevent non-steroidal anti-inflammatory drug (NSAID)-associated gastroduodenal complications. There is, however, limited information regarding the efficacy of DA-9601 in this context. We performed a comparative study on the relative efficacy of DA-9601 and misoprostol for prevention of NSAID-associated complications. In this multicenter, double-blinded, active-controlled, stratified randomized, parallel group, non-inferiority trial, 520 patients who were to be treated with an NSAID (aceclofenac, 100 mg, twice daily) over a 4-week period were randomly assigned to groups for coincidental treatment with DA-9601 (60 mg, thrice daily) (236 patients for full analysis) or misoprostol (200 μg, thrice daily) (242 patients for full analysis). A total of 236 patients received DA-9601 and 242 received misoprostol. The primary endpoint was the gastric protection rate, and secondary endpoints were the duodenal protection rate and ulcer incidence rate. Endpoints were assessed by endoscopy after the 4-week treatment period. Drug-related adverse effects, including gastrointestinal (GI) symptoms, were also compared. At week 4, the gastric protection rates with DA-9601 and misoprostol were 81.4 % (192/236) and 89.3 % (216/242), respectively. The difference between the groups was -14.2 %, indicating non-inferiority of DA-9601 to misoprostol. Adverse event rates were not different between the two groups; however, the total scores for GI symptoms before and after administration were significantly lower in the DA-9601 group than in the misoprostol group (-0.2 ± 2.8 vs 1.2 ± 3.2; p < 0.0001). DA-9601 is as effective as misoprostol in preventing NSAID-associated gastroduodenal complications, and has a superior adverse GI effect profile.

Original languageEnglish
Pages (from-to)1308-1316
Number of pages9
JournalArchives of Pharmacal Research
Volume37
Issue number10
DOIs
Publication statusPublished - 2014 Oct 1

Fingerprint

Drug therapy
Misoprostol
Anti-Inflammatory Agents
Wounds and Injuries
Pharmaceutical Preparations
Therapeutics
Stomach
Endoscopy
DA 9601
Ulcer
Incidence

Keywords

  • DA-9601(Stilen<sup>®</sup>)
  • Gastroduodenal injury
  • Misoprostol
  • NSAID-associated

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Organic Chemistry

Cite this

A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. / Lee, Oh Young; Kang, Dae Hwan; Lee, Dong Ho; Chung, Il Kwun; Jang, Jae Young; Kim, Jin Il; Cho, Jin Woong; Rew, Jong Sun; Lee, Kang Moon; Kim, Kyoung Oh; Choi, Myung Gyu; Lee, Sang Woo; Lee, Soo Teik; Kim, Tae Oh; Shin, Yong Woon; Seol, Sang Yong.

In: Archives of Pharmacal Research, Vol. 37, No. 10, 01.10.2014, p. 1308-1316.

Research output: Contribution to journalArticle

Lee, OY, Kang, DH, Lee, DH, Chung, IK, Jang, JY, Kim, JI, Cho, JW, Rew, JS, Lee, KM, Kim, KO, Choi, MG, Lee, SW, Lee, ST, Kim, TO, Shin, YW & Seol, SY 2014, 'A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment', Archives of Pharmacal Research, vol. 37, no. 10, pp. 1308-1316. https://doi.org/10.1007/s12272-014-0408-3
Lee, Oh Young ; Kang, Dae Hwan ; Lee, Dong Ho ; Chung, Il Kwun ; Jang, Jae Young ; Kim, Jin Il ; Cho, Jin Woong ; Rew, Jong Sun ; Lee, Kang Moon ; Kim, Kyoung Oh ; Choi, Myung Gyu ; Lee, Sang Woo ; Lee, Soo Teik ; Kim, Tae Oh ; Shin, Yong Woon ; Seol, Sang Yong. / A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. In: Archives of Pharmacal Research. 2014 ; Vol. 37, No. 10. pp. 1308-1316.
@article{e9ae902fc207408395f0396acdf9b6ea,
title = "A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment",
abstract = "Misoprostol is reported to prevent non-steroidal anti-inflammatory drug (NSAID)-associated gastroduodenal complications. There is, however, limited information regarding the efficacy of DA-9601 in this context. We performed a comparative study on the relative efficacy of DA-9601 and misoprostol for prevention of NSAID-associated complications. In this multicenter, double-blinded, active-controlled, stratified randomized, parallel group, non-inferiority trial, 520 patients who were to be treated with an NSAID (aceclofenac, 100 mg, twice daily) over a 4-week period were randomly assigned to groups for coincidental treatment with DA-9601 (60 mg, thrice daily) (236 patients for full analysis) or misoprostol (200 μg, thrice daily) (242 patients for full analysis). A total of 236 patients received DA-9601 and 242 received misoprostol. The primary endpoint was the gastric protection rate, and secondary endpoints were the duodenal protection rate and ulcer incidence rate. Endpoints were assessed by endoscopy after the 4-week treatment period. Drug-related adverse effects, including gastrointestinal (GI) symptoms, were also compared. At week 4, the gastric protection rates with DA-9601 and misoprostol were 81.4 {\%} (192/236) and 89.3 {\%} (216/242), respectively. The difference between the groups was -14.2 {\%}, indicating non-inferiority of DA-9601 to misoprostol. Adverse event rates were not different between the two groups; however, the total scores for GI symptoms before and after administration were significantly lower in the DA-9601 group than in the misoprostol group (-0.2 ± 2.8 vs 1.2 ± 3.2; p < 0.0001). DA-9601 is as effective as misoprostol in preventing NSAID-associated gastroduodenal complications, and has a superior adverse GI effect profile.",
keywords = "DA-9601(Stilen<sup>{\circledR}</sup>), Gastroduodenal injury, Misoprostol, NSAID-associated",
author = "Lee, {Oh Young} and Kang, {Dae Hwan} and Lee, {Dong Ho} and Chung, {Il Kwun} and Jang, {Jae Young} and Kim, {Jin Il} and Cho, {Jin Woong} and Rew, {Jong Sun} and Lee, {Kang Moon} and Kim, {Kyoung Oh} and Choi, {Myung Gyu} and Lee, {Sang Woo} and Lee, {Soo Teik} and Kim, {Tae Oh} and Shin, {Yong Woon} and Seol, {Sang Yong}",
year = "2014",
month = "10",
day = "1",
doi = "10.1007/s12272-014-0408-3",
language = "English",
volume = "37",
pages = "1308--1316",
journal = "Archives of Pharmacal Research",
issn = "0253-6269",
publisher = "Pharmaceutical Society of Korea",
number = "10",

}

TY - JOUR

T1 - A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment

AU - Lee, Oh Young

AU - Kang, Dae Hwan

AU - Lee, Dong Ho

AU - Chung, Il Kwun

AU - Jang, Jae Young

AU - Kim, Jin Il

AU - Cho, Jin Woong

AU - Rew, Jong Sun

AU - Lee, Kang Moon

AU - Kim, Kyoung Oh

AU - Choi, Myung Gyu

AU - Lee, Sang Woo

AU - Lee, Soo Teik

AU - Kim, Tae Oh

AU - Shin, Yong Woon

AU - Seol, Sang Yong

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Misoprostol is reported to prevent non-steroidal anti-inflammatory drug (NSAID)-associated gastroduodenal complications. There is, however, limited information regarding the efficacy of DA-9601 in this context. We performed a comparative study on the relative efficacy of DA-9601 and misoprostol for prevention of NSAID-associated complications. In this multicenter, double-blinded, active-controlled, stratified randomized, parallel group, non-inferiority trial, 520 patients who were to be treated with an NSAID (aceclofenac, 100 mg, twice daily) over a 4-week period were randomly assigned to groups for coincidental treatment with DA-9601 (60 mg, thrice daily) (236 patients for full analysis) or misoprostol (200 μg, thrice daily) (242 patients for full analysis). A total of 236 patients received DA-9601 and 242 received misoprostol. The primary endpoint was the gastric protection rate, and secondary endpoints were the duodenal protection rate and ulcer incidence rate. Endpoints were assessed by endoscopy after the 4-week treatment period. Drug-related adverse effects, including gastrointestinal (GI) symptoms, were also compared. At week 4, the gastric protection rates with DA-9601 and misoprostol were 81.4 % (192/236) and 89.3 % (216/242), respectively. The difference between the groups was -14.2 %, indicating non-inferiority of DA-9601 to misoprostol. Adverse event rates were not different between the two groups; however, the total scores for GI symptoms before and after administration were significantly lower in the DA-9601 group than in the misoprostol group (-0.2 ± 2.8 vs 1.2 ± 3.2; p < 0.0001). DA-9601 is as effective as misoprostol in preventing NSAID-associated gastroduodenal complications, and has a superior adverse GI effect profile.

AB - Misoprostol is reported to prevent non-steroidal anti-inflammatory drug (NSAID)-associated gastroduodenal complications. There is, however, limited information regarding the efficacy of DA-9601 in this context. We performed a comparative study on the relative efficacy of DA-9601 and misoprostol for prevention of NSAID-associated complications. In this multicenter, double-blinded, active-controlled, stratified randomized, parallel group, non-inferiority trial, 520 patients who were to be treated with an NSAID (aceclofenac, 100 mg, twice daily) over a 4-week period were randomly assigned to groups for coincidental treatment with DA-9601 (60 mg, thrice daily) (236 patients for full analysis) or misoprostol (200 μg, thrice daily) (242 patients for full analysis). A total of 236 patients received DA-9601 and 242 received misoprostol. The primary endpoint was the gastric protection rate, and secondary endpoints were the duodenal protection rate and ulcer incidence rate. Endpoints were assessed by endoscopy after the 4-week treatment period. Drug-related adverse effects, including gastrointestinal (GI) symptoms, were also compared. At week 4, the gastric protection rates with DA-9601 and misoprostol were 81.4 % (192/236) and 89.3 % (216/242), respectively. The difference between the groups was -14.2 %, indicating non-inferiority of DA-9601 to misoprostol. Adverse event rates were not different between the two groups; however, the total scores for GI symptoms before and after administration were significantly lower in the DA-9601 group than in the misoprostol group (-0.2 ± 2.8 vs 1.2 ± 3.2; p < 0.0001). DA-9601 is as effective as misoprostol in preventing NSAID-associated gastroduodenal complications, and has a superior adverse GI effect profile.

KW - DA-9601(Stilen<sup>®</sup>)

KW - Gastroduodenal injury

KW - Misoprostol

KW - NSAID-associated

UR - http://www.scopus.com/inward/record.url?scp=84938877822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938877822&partnerID=8YFLogxK

U2 - 10.1007/s12272-014-0408-3

DO - 10.1007/s12272-014-0408-3

M3 - Article

VL - 37

SP - 1308

EP - 1316

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

SN - 0253-6269

IS - 10

ER -